Long-term Beta-blocker Therapy After Acute Myocardial Infarction

Summary

The aim of the study is to determine whether discontinuation of β-blocker after at least 1 year of β-blocker therapy is noninferior to continuation of β-blocker in patients without heart failure (HF) or left ventricular systolic dysfunction after acute myocardial infarction (AMI).

Prospective, open-label, randomized, multicenter, noninferiority trial to determine whether discontinuation of β-blocker after at least 1 year of β-blocker therapy is noninferior to continuation of β-blocker in patients without HF or left ventricular systolic dysfunction after AMI.

Conditions

• Myocardial Infarction

Interventions

DRUG

Discontinuation of β-blocker

Discontinuation of β-blocker after at least 1 year of β-blocker therapy after acute myocardial infarction

Sponsors & Collaborators

• Kangbuk Samsung Hospital

  collaborator OTHER

• Gyeongsang National University Hospital

  collaborator OTHER

• Kyung Hee University Hospital

  collaborator OTHER

• Keimyung University Dongsan Medical Center

  collaborator OTHER

• Korea University Anam Hospital

  collaborator OTHER

• Sejong General Hospital

  collaborator OTHER

• Seoul National University Bundang Hospital

  collaborator OTHER

• Samsung Changwon Hospital

  collaborator OTHER

• Saint Vincent's Hospital, Korea

  collaborator OTHER

• Presbyterian medical center

  collaborator UNKNOWN

• Wonkwang University Hospital

  collaborator OTHER

• Wonju Severance Christian Hospital

  collaborator OTHER

• Ewha Womans University Seoul Hospital

  collaborator OTHER

• Inje University Ilsan Paik Hospital

  collaborator OTHER

• Chonbuk National University Hospital

  collaborator OTHER

• Chonnam National University Hospital

  collaborator OTHER

• Jeju National University Hospital

  collaborator OTHER

• Chosun University Hospital

  collaborator OTHER

• Chungbuk National University Hospital

  collaborator OTHER

• Chungnam National University Hospital

  collaborator OTHER

• Samsung Medical Center

  lead OTHER

Principal Investigators

• Joo-Yong Hahn, MD,PhD · Samsung Medical Center, Sungkyunkwan University School of Medicine

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

19 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-05-04

Primary Completion

2026-01-31

Completion

2026-03-31

Countries

• South Korea

Study Locations